UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 14, 2004
BIOPHAN TECHNOLOGIES, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
NEVADA 0-26057 82-0507874
----------------------------- ------------- -----------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
150 LUCIUS GORDON DRIVE, SUITE 215
WEST HENRIETTA, NEW YORK 14586
--------------------------------------- ---------
(Address of principal executive offices) (Zip code)
(585) 214-2441
-------------------------
(Registrant's telephone number)
- 2-
Item 9. Regulation FD Disclosure
On May 14, 2004, the Company agreed to acquire a 51% ownership interest in
TE-Bio, LLC ("TE-Bio") and to perform certain services for TE-Bio (the
"Agreement"). The Agreement provides for the Company to invest $300,000 per year
in TE-Bio for a period of three years. In addition, the Company will provide
certain administrative, marketing and R&D services to TE-Bio.
TE-Bio is working with technology based on a patented innovation developed by
Biomed Solutions, LLC in the utilization of thermoelectric materials, using
nanoscale-based, thin-film materials to convert thermal energy produced
naturally by the human body into electrical energy. The resulting power may then
be used to "trickle charge" batteries for medium-power devices such as
defibrillators, or directly power low-energy devices like pacemakers. TE-Bio is
developing an implantable power system that has the potential to provide as much
as a 30-year life -- a five-fold increase in service life compared to existing
technology. Since medical devices are implanted in young patients, the
combination of the TE-Bio technology and extended medical device life may reduce
the number of replacement implants needed throughout a patient's life.
The Company will assist TE-Bio in pursuing R&D agreements with other companies
involved in thermoelectric research and identifying potential sources of
government sponsored R&D.
- 3 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHAN TECHNOLOGIES, INC.
--------------------------
(Registrant)
Date 5/18/2004 /s/ Robert J. Wood
---------------- --------------------------
(Signature)
Robert J. Wood
CFO, Treasurer
(Principal Financial Officer)